Home
This site is intended for healthcare professionals

Alcohol Use Disorders (AUD): Practice in Action

Share

Description

This program is supported by an independent educational grant from Lilly.

Originally presented at the 26th World Congress of Psychiatry, Stockholm, Sweden, 25 September 2026

Watch this in:

Revisit this expert-led symposium with Nestor Szerman, Amandine Luquiens, and Khaled Moussawi, exploring practical approaches to identifying, treating, and coordinating care for people with alcohol use disorder (AUD).

Through a longitudinal patient case, the symposium follows three key clinical decision points—from recognizing and diagnosing AUD to developing an individualized treatment plan and coordinating ongoing care.

What will you explore?

  • Identify and diagnose AUD — recognize presentations that may be overlooked, use validated screening tools, and distinguish screening from diagnostic assessment and severity classification.
  • Align treatment with patient goals — explore patient-centered approaches to treatment goals and consider how pharmacological and behavioral interventions can be integrated into care.
  • Coordinate care across services — examine how psychiatrists, addiction specialists, behavioral therapists, primary care, and community support can work together around a shared care plan.
  • Monitor and adapt treatment — consider how alcohol use, craving, mood, functioning, treatment response, and safety can inform ongoing management and escalation of care.

Revisit the symposium

Explore the clinical decisions, evidence, and practical strategies discussed at WCP 2026, and consider how these approaches could be applied in your own practice.

Prefer to read? See our Key Clinical Summary here in your preferred language:

Faculty

Néstor Szerman, MD

Dr Néstor Szerman is a psychiatrist and expert in addiction and dual disorders. He is Head of the “Retiro” Mental Health Service at Gregorio Marañón University Hospital in Madrid and Advising Psychiatrist for Alcoholism and Dual Disorders within Madrid Public Mental Health. He is Associate Professor in Drug Dependence at Complutense University of Madrid and has contributed to international guidelines and consensus recommendations on addictive disorders, including alcohol use disorder and opioid use disorder. His clinical and research interests focus on addiction and co-occurring psychiatric disorders.

Amandine Luquiens, MD PhD

Professor Amandine Luquiens is a psychiatrist and addiction specialist at the University of Montpellier and Nîmes University Hospital, France. She holds a PhD in Cognitive Sciences, with her doctoral research focused on quality of life in alcohol use disorder (AUD).

Her clinical and research work focuses on AUD, patient-centred approaches to addiction care, quality of life, early detection, and innovative psychological interventions. She has published extensively on alcohol-related outcomes and treatment, including harm-reduction approaches and emerging therapies for AUD.

Khaled Moussawi, MD, PhD

Dr Khaled Moussawi is an Associate Professor of Neurology and Psychiatry at the University of California, San Francisco (UCSF) and holds the Howard L. Fields Endowed Chair in Pharmacology of Addiction. His research focuses on the neurobiology of substance use disorders and developing novel neuromodulation approaches to treat addiction.

His work includes research into alcohol use disorder (AUD), including the use of transcranial focused ultrasound and deep brain stimulation to target neural circuits involved in craving and alcohol-seeking behaviours. He is Principal Investigator of clinical studies investigating neuromodulation approaches for AUD.

Disclosures

In accordance with EBAC® guidelines, all speakers and moderators participating in this program have declared or indicated any potential conflicts of interest that could bias their presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are disclosed to the audience before the start of the continuing education activities.

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Néstor Szerman, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies:: Advisor for Eli Lilly, Consultant for Eli Lilly, Grant/Research Support from Gidoen Richter, Recordati, Speaker for Gidoen Richter, Recordati. Nestor Szerman MD does intend to reference unlabeled or unapproved uses of products during the presentation.

Amandine Luquiens, MD PhD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisor for Johnson and Johnson and Camrus, Consultant for Johnson and Johnson and Camrus, Speaker for Johnson and Johnson and Camrus. Amandine Luquiens, MD PhD, does intend to reference unlabeled or unapproved uses of products during the presentation.

Khaled Moussawi, MD, PhD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisor for Ely Lilly, Consultant for Eli Lilly, Speaker for Eli Lilly. Khaled Moussawi, MD, PhD, does intend to reference unlabeled or unapproved uses of products during the presentation.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-323-H01-P

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

EBAC® CME Information:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

MedAll is an EBAC accredited provider since 2025. The European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredits Continuing Education (CE) programmes for the international medical community.

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for one hour of effective education time.

In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.

The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

How to Obtain Your EBAC® CME Credit:

To obtain your CME credit and acquire your certificate, please engage with the activity and complete the evaluation at the end. You will receive a link to your certificate after completing the evaluation.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting October 2nd 2026, and will expire on September 25th 2027.

Learning objectives

After completing this activity HCP's should be better able to:

• Implement validated screening guidelines, tools, and DSM-5-TR diagnostic criteria within clinical workflows to accurately identify and document AUD across the full severity spectrum (mild, moderate, severe) in ≥ 80% of case-based exercises.

• Formulate patient-centered AUD treatment plans that align with individualized goals (reduction or abstinence) and appropriately initiate evidence-based pharmacologic and behavioral treatment strategies without universally requiring prior abstinence in ≥ 75% of simulated clinical scenarios.

• Execute coordinated, multidisciplinary care pathways that integrate pharmacotherapy, psychotherapy, peer support, and structured follow-up, clearly defining team roles, referral pathways, and accountability processes in ≥ 80% of team-based application exercises.

• Evaluate and apply emerging clinical research and updated guideline recommendations to optimize AUD management workflows and reduce delays in adoption of evidence-based practices in ≥ 70% of implementation-planning exercises.

Similar communities

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Thank you for, uh, to organizing for this kind invitation to be here. It's a pleasure to, to be here. And welcome, welcome all attendees, friends and colleagues at this educational session. This afternoon. In this session, in this educational session, we are going to talk about in some ways and explore maybe orphan topic in our field. We are talking about alcohol use disorder. For, from now on, AUD. This, uh, session will focus on practical decisions rather than a comprehensive review of the concept of AUD. We would like to have an interactive session. This is an educational session, and we, we would like to have an interactive session with all of you. With that in mind, we have prepared some polling questions. If I can move, OK. We have prepared some polling questions and you need to, to scan the, the QR in order to interact with. With us and with all of you. The first full question is, uh, what is the greatest challenge in EUD in EUD curve in your setting. Maybe identifying and diagnosis AUD or initiating appropriate treatment or coordinating a care across services or translating evidence into practice. Is there not single uh uh right answer is a mm. And a question that we need to identify the key points that are very important in order to treat our patient with this clinical condition that is called AUD. A patient with AUD can fail at several points in this session, we, we try to help you to translate those gap into practical decisions. OK There are different OK, this is the question. If some time needs to To vote later. Can show the the next slide please the answers. OK. OK, thank you for your answers. Uh, most people with AUD do not receive treatment. Uh, as you can see, a few, a minority of people with AUD receive an appropriate treatment, despite we are effective treatment for this clinical condition for treat AUD. What, what is the reason? This is the reason that we are here in this educational session. Uh, the overall, uh. ratio is very, very low. OK. And the answer is OK, now. OK. Sorry, because they are so low, the, the, the slides. Uh Um, this is not due to a single wrong decision, uh. We can drink. Working now? No, OK. OK, this is the, the, I was telling that it's not, uh, due to a single wrong decision. The care gap is a cascade, not a single missed decision. Patience can be lost, can be lost at multiple points between identification. The use of alcohol, diagnosing uh uh AUD, the treatment, the initiating treatment of AUD, the engagement of the patient in the treatment, and finally, the ongoing care. Finding AUD is important, is necessary, is crucial, but it does not guarantee that patients reach or remain in treatment. OK. We, we are Structure this session and different clinical decisions. We are, we, we follow up the therapeutic process of one patient and we are making, we need three different decisions. The first important, crucial decision is identify and diagnose people with, they are using alcohol. What are we dealing with? The second decision point will be plan and treat our patients. What should we go? What should we do? And finally, coordinated and follow up. How do we make it happen? Evidence of course inform each decision. You make the decision first. The symposium will turn the care gap into practical decision around this longitudinal follow up of a patient. OK, we are moving from the, I think that. OK. Now, we are moving to the decision point first. Amandin, can you tell us about this? Uh, decision point first identification and diagnosis. Sorry, thank you, yeah, sorry, thank you for the pointer, yeah, so. Please, uh, meet, uh, Elena. Uh, she's, uh, your patient for today, and, uh, she will help us understanding the challenges we face, um, in AUD. So Elena first went to visit you. You are her new, uh, um, psychiatrist, and she's 48 years old. She, she's full-time employed. She has her partner. And she is referred for persistent mood and anxiety symptoms. So this is what you know when you meet her and you can identify this low mood, this anxiety, but also Poor sleep and a reduced concentration. He also finds that she already has an antidepressant, uh, but she has an incomplete response. So to this point, Elena tells you nothing about alcohol. And it's very frequent in patients because of the stigma we'll talk about later in the next slide. And also because she could be not aware of the impact of any alcohol use in these symptoms. So it's very important to have this in mind uh when interviewing Elena. um because alcohol use disorder may be first present, oh, so it's runs by itself. I don't know why. Yeah, OK, sorry. AUD may be first present through another psychiatric complaint. So this is not us for changing the slide. Yeah. OK, you do it. So what else uh would we, um, would you want to know about Elina to have a very complete and deep assessment of her current uh mental state? So this is what you already know. What do we want to know? Yeah, maybe you can display. The things, oh. No, sometimes it works and sometimes it does not. So sorry for the technical mess. OK. Shall we try again? Forward, yeah, OK. So what we want to know, sorry for the interruption, uh, is, as I mentioned before, um, has, um, has she, um, already have an alcohol and substance use history in the past, but also of course in the present. Um, we know that she has an incomplete response to antidepressant, but does she really takes the pills? Uh, do we have a medication adherent here? Uh, does she also presents a maniac or hypomaniac symptoms and of course, uh, in front of her depressed mood we have always to check on any suicidal risk. Uh, we should also know if she has any medical condition that could contribute to her current state. So the alcohol assessment should be part of the psychiatric diagnostic workup and not an afterthought. So here are 3 few and very simple questions you can ask to Elena. The first one is how often do you have a drink containing alcohol in the past year? And Helena would answer if you ask her. Uh, most evenings, usually I have wine with dinner. The second question is how many drinks containing alcohol did you have on a typical day when you were drinking in the past year? So it's really a global assessment of the past year before the visit. And she would say normally 3 or 4 drinks, sometimes more at the weekends.